"Humanization of Antibodies using a Statistical Inference Approach" -- Supplementary Data
Alejandro Clavero-Álvarez, Tomas Di Mambro, Sergio Perez-Gaviro, Mauro Magnani, Pierpaolo Bruscolini

This file reports the sequences used in our studies, and found in the Drugbank repository (see text). The sequences are AHo-aligned: first 149 positions: VH, second 149: VL. They are preceded by the min-max value of immunogenicity reported in literature (When the reference is not reported below the sequence, please refer to the bibliography mentioned in the article)


MURINE Ab:
>3F8
100 100 QVQLKES-GPGLVAPSQSLSITCTVSG-FSVTN-----YGVHWVRQPPGKGLEWLGVIWA----GGITNYNSAFMSRLSISKDNSKSQVFLKMNSLQIDDTAMYYCASRGGHY-------------------GYALDYWGQGTSVTVSSSIVMTQTPKFLLVSAGDRVTITCKAS--QSVS------NDVTWYQQKAGQSPKLLIYS--------ASNRYSGVPDRFTGSGYG--TAFTFTISTVQAEDLAVYFCQQDY--------------------------SSFGGGTKLEIKR
>moAb 81C6 
100 100 EVQLQQS-GPELVKPGASVKMSCKASG-YTFTS-----YVVHWVKQNPGQGLEWIGYINPF---NDGTKYNENFKGKATLTSDRSSSTAYMELSSLTSEESAVYFCARDMGR---------------------EGFAYWGQGTLVTVSADIVMTQAAFSNPVTLGTSASISCRSS--KSLLHSN-GITYLYWYLQKPGQSPQLLIYQ--------MSNLASGVPDRFSSSGSG--TDFTLRISRVEAEDVGVYYCAQNLE-----------------------LPRTFGGGTKLEI--
>Arcitumomab 1clo:Anti-CEA  chain 1 
0 1 EVKLVES-GGGLVQPGGSLRLSCATSG-FTFTD-----YYMNWVRQPPGKALEWLGFIGNKA-NGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLR--------------------FYFDYWGQGTTLTVSSQTVLSQSPAILSASPGEKVTMTCRAS--SSVT-------YIHWYQQKPGSSPKSWIYA--------TSNLASGVPARFSGSGSG--TSYSLTISRVEAEDAATYYCQHWSS-----------------------KPPTFGGGTKLEIK-
>Blinatumomab single chain variable fragment fusion protein  Chain 1 
1.4 1.4 QVQLQQS-GAELVRPGSSVKISCKASG-YAFSS-----YWMNWVKQRPGQGLEWIGQIWPG---DGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVG---------------RYYYAMDYWGQGTTVTVSSDIQLTQSPASLAVSLGQRATISCKAS--QSVDYD--GDSYLNWYQQIPGQPPKLLIYD--------ASNLVSGIPPRFSGSGSG--TDFTLNIHPVEKVDAATYHCQQSTE-----------------------DPWTFGGGTKLEIK-
https://ec.europa.eu/health/documents/community-register/2015/20151123133349/anx_133349_it.pdf 
>Blinatumomab single chain variable fragment fusion protein Chain 2
1.4 1.4 DIKLQQS-GAELARPGASVKMSCKTSG-YTFTR-----YTMHWVKQRPGQGLEWIGYINPS---RGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDH--------------------YCLDYWGQGTTLTVSSDIQLTQSPAIMSASPGEKVTMTCRAS--SSVS-------YMNWYQQKSGTSPKRWIYD--------TSKVASGVPYRFSGSGSG--TSYSLTISSMEAEDAATYYCQQWSS-----------------------NPLTFGAGTKLELK-
https://ec.europa.eu/health/documents/community-register/2015/20151123133349/anx_133349_it.pdf 
>Ibritumomab tiuxetan  
1.3 2.5 QAYLQQS-GAELVRPGASVKMSCKASG-YTFTS-----YNMHWVKQTPRQGLEWIGAIYPG---NGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSN-----------------SYWYFDVWGTGTTVTVSAQIVLSQSPAILSASPGEKVTMTCRAS--SSVS-------YMHWYQQKPGSSPKPWIYA--------PSNLASGVPARFSGSGSG--TSYSLTISRVEAEDAATYYCQQWSF-----------------------NPPTFGAGTKLELK-
>Muromonab-CD3  
26 86 QVQLQQS-GAELARPGASVKMSCKASG-YTFTR-----YTMHWVKQRPGQGLEWIGYINPS---RGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDH--------------------YCLDYWGQGTTLTVSSQIVLTQSPAIMSASPGEKVTMTCSAS--SSVS-------YMNWYQQKSGTSPKRWIYD--------TSKLASGVPAHFRGSGSG--TSYSLTISGMEAEDAATYYCQQWSS-----------------------NPFTFGSGTKLEINR
>Satumomab Pendetide  chain 1 B72.3 (murine) 
55 55 QVQLQQS-DAELVKPGASVKISCKASG-YTFTD-----HAIHWAKQKPEQGLEWIGYISPG---NDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSY-------------------------YGHWGQGTTLTVSSDIQMTQSPASLSVSVGETVTITCRAS--ENIY------SNLAWYQQKQGKSPQLLVYA--------ATNLADGVPSRFSGSGSG--TQYSLKINSLQSEDFGSYYCQHFWG-----------------------TPYTFGGGTRLEIK-
>Tositumomab Mouse-Human chimeric Anti-CD20 Chain 1 
11 64 QAYLQQS-GAELVRPGASVKMSCKASG-YTFTS-----YNMHWVKQTPRQGLEWIGAIYPG---NGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSN-----------------SYWYFDVWGTGTTVTVSGQIVLSQSPAILSASPGEKVTMTCRAS--SSVS-------YMHWYQQKPGSSPKPWIYA--------PSNLASGVPARFSGSGSG--TSYSLTISRVEAEDAATYYCQQWSF-----------------------NPPTFGAGTKLELK-

CHIMERIC Ab:
>Abciximab 1TXV:H ReoPro-like antibody  Chain 1 
27 44    EVQLQQS-GAELVKPGASVKLSCTASG-FNIKD-----TYVHWVKQRPEQGLEWIGRIDPA---NGYTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDY--------------------YAMDYWGQGTSVTVSSDILMTQSPSSMSVSLGDTVSITCHAS--QGIS------SNIGWLQQKPGKSFMGLIYY--------GTNLVDGVPSRFSGSGSG--ADYSLTISSLDSEDFADYYCVQYAQ-----------------------LPYTFGGGTKLEIK-
>Basiliximab  
1 2 --QLQQS-GTVLARPGASVKMSCKASG-YSFTR-----YWMHWIKQRPGQGLEWIGAIYPG---NSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGY----------------------YFDFWGQGTTLTVSSQIVSTQSPAIMSASPGEKVTMTCSAS--SSRS-------YMQWYQQKPGTSPKRWIYD--------TSKLASGVPARFSGSGSG--TSYSLTISSMEAEDAATYYCHQRS-------------------------SYTFGGGTKLEIK-
>Bavituximab 8734_H
51 65 EVQLQQS-GPELEKPGASVKLSCKASG-YSFTG-----YNMNWVKQSHGKSLEWIGHIDPY---YGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYG-------------------HWYFDVWGAGTTVTVSSDIQMTQSPSSLSASLGERVSLTCRAS--QDIG------SSLNWLQQGPDGTIKRLIYA--------TSSLDSGVPKRFSGSRSG--SDYSLTISSLESEDFVDYYCLQYVS-----------------------SPPTFGAGTKLELK-
>Cetuximab chain 
5 5  QVQLKQS-GPGLVQPSQSLSITCTVSG-FSLTN-----YGVHWVRQSPGKGLEWLGVIWS----GGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYY-------------------DYEFAYWGQGTLVTVS-DILLTQSPVILSVSPGERVSFSCRAS--QSIG------TNIHWYQQRTNGSPRLLIKY--------ASESISGIPSRFSGSGSG--TDFTLSINSVESEDIADYYCQQNNN-----------------------WPTTFGAGTKLELK-
>Rituximab  chimeric 
11 11 QVQLQQP-GAELVKPGASVKMSCKASG-YTFTS-----YNMHWVKQTPGRGLEWIGAIYPG---NGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGG------------------DWYFNVWGAGTTVTVSAQIVLSQSPAILSASPGEKVTMTCRAS--SSVS-------YIHWFQQKPGSSPKPWIYA--------TSNLASGVPVRFSGSGSG--TSYSLTISRVEAEDAATYYCQQWTS-----------------------NPPTFGGGTKLEIK-
>Siltuximab Sequence 
0.2 0.2 EVQLVES-GGKLLKPGGSLKLSCAASG-FTFSS-----FAMSWFRQSPEKRLEWVAEISSG---GSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGY--------------------YALDYWGQGTSVTVSSQIVLIQSPAIMSASPGEKVTMTCSAS--SSVS-------YMYWYQQKPGSSPRLLIYD--------TSNLASGVPVRFSGSGSG--TSYSLTISRMEAEDAATYYCQQWSG-----------------------YPYTFGGGTKLEIK-


HUMANIZED Ab:
>Alemtuzumab: 1CE1:H CAMPATH-1H:Chain 1 
1.9 8.3 QVQLQES-GPGLVRPSQTLSLTCTVSG-FTFTD-----FYMNWVRQPPGRGLEWIGFIRDKA-KGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTA--------------------APFDYWGQGSLVTVSSDIQMTQSPSSLSASVGDRVTITCKAS--QNID------KYLNWYQQKPGKAPKLLIYN--------TNNLQTGVPSRFSGSGSG--TDFTFTISSLQPEDIATYYCLQHIS-----------------------RPRTFGQGTKVEIK-
>Atezolizumab: 
16.7 41.9 EVQLVES-GGGLVQPGGSLRLSCAASG-FTFSD-----SWIHWVRQAPGKGLEWVAWISPY---GGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWP---------------------GGFDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCRAS--QDVS------TAVAWYQQKPGKAPKLLIYS--------ASFLYSGVPSRFSGSGSG--TDFTLTISSLQPEDFATYYCQQYLY-----------------------HPATFGQGTKVEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000ClinPharmR.pdf 
>Bevacizumab: 
0 0.63  EVQLVES-GGGLVQPGGSLRLSCAASG-YTFTN-----YGMNWVRQAPGKGLEWVGWINTY---TGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGS----------------SHWYFDVWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCSAS--QDIS------NYLNWYQQKPGKAPKVLIYF--------TSSLHSGVPSRFSGSGSG--TDFTLTISSLQPEDFATYYCQQYST-----------------------VPWTFGQGTKVEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125085s301lbl.pdf
>Certolizumab pegol: 
9.1 15  EVQLVES-GGGLVQPGGSLRLSCAASG-YVFTD-----YGMNWVRQAPGKGLEWMGWINTY---IGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRS---------------------YAMDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCKAS--QNVG------TNVAWYQQKPGKAPKALIYS--------ASFLYSGVPYRFSGSGSG--TDFTLTISSLQPEDFATYYCQQYNI-----------------------YPLTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf
>Daclizumab:  
19 19 QVQLVQS-GAEVKKPGSSVKVSCKASG-YTFTS-----YRMHWVRQAPGQGLEWIGYINPS---TGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGG-----------------------VFDYWGQGTTLTVSSDIQMTQSPSTLSASVGDRVTITCSAS--SSIS-------YMHWYQQKPGKAPKLLIYT--------TSNLASGVPARFSGSGSG--TEFTLTISSLQPDDFATYYCHQRST-----------------------YPLTFGSGTKVEVK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/003862/WC500210598.pdf
>Elotuzumab:  
18.5 18.5 EVQLVES-GGGLVQPGGSLRLSCAASG-FDFSR-----YWMSWVRQAPGKGLEWIGEINPD---SSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNY--------------------WYFDVWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCKAS--QDVG------IAVAWYQQKPGKVPKLLIYW--------ASTRHTGVPDRFSGSGSG--TDFTLTISSLQPEDVATYYCQQYSS-----------------------YPYTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf
>Farletuzumab: 9067_H
EVQLVES-GGGVVQPGRSLRLSCSASG-FTFSG-----YGLSWVRQAPGKGLEWVAMISSG---GSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDP--------------------AWFAYWGQGTPVTVSSDIQLTQSPSSLSASVGDRVTITCSVS--SSISS-----NNLHWYQQKPGKAPKPWIYG--------TSNLASGVPSRFSGSGSG--TDYTFTISSLQPEDIATYYCQQWSSY---------------------PYMYTFGQGTKVEIK-
>Gemtuzumab ozogamicin  Chain No. 2  (humanized)
0 0 QVQLVQS-GAEVKKPGSSVKVSCKASG-GTFSR-----SAIIWVRQAPGQGLEWMGGIVPM---FGPPNYAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGI----------------------YSPEEYNGGLVTVSSDIQMTQSPSTLSASVGDRVTITCRAS--QSIN------TWLAWYQQKPGKAPKLLMYK--------ASSLESGVPSRFIGSGSG--TEFTLTISSLQPDDFATYYCQQYNS-----------------------DSKMFGQGTKVEVK-
>Idarucizumab:  
4 4 QVQLQES-GPGLVKPSETLSLTCTVSG-FSLTS-----YIVDWIRQPPGKGLEWIGVIWA----GGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYY----------------NYDGFAYWGQGTLVTVSSDVVMTQSPLSLPVTLGQPASISCKSS--QSLLYTD-GKTYLYWFLQRPGQSPRRLIYL--------VSKLDSGVPDRFSGSGSG--TDFTLKISRVEAEDVGVYYCLQSTH-----------------------FPHTFGGGTKVEIK-
https://ec.europa.eu/health/documents/community-register/2015/20151120133203/anx_133203_it.pdf
>Ixekizumab: 
9  17 QVQLVQS-GAEVKKPGSSVKVSCKASG-YSFTD-----YHIHWVRQAPGQGLEWMGVINPM---YGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFT--------------------GTGVYWGQGTLVTVSSDIVMTQTPLSLSVTPGQPASISCRSS--RSLVHSR-GNTYLHWYLQKPGQSPQLLIYK--------VSNRFIGVPDRFSGSGSG--TDFTLKISRVEAEDVGVYYCSQSTH-----------------------LPFTFGQGTKLEIK-
https://ec.europa.eu/health/documents/community-register/2017/20170907138842/anx_138842_it.pdf 
>Matuzumab: 3c08_H|Fab72000|Humanized
QVQLVQS-GAEVKKPGASVKVSCKASG-YTFTS-----HWMHWVRQAPGQGLEWIGEFNPS---NGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYD------------------GRYFDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCSAS--SSVT-------YMYWYQQKPGKAPKLLIYD--------TSNLASGVPSRFSGSGSG--TDYTFTISSLQPEDIATYYCQQWSS-----------------------HIFTFGQGTKVEIK-
>Matuzumab: 3c09_C|Fab72000|Humanized 
QVQLVQS-GAEVKKPGASVKVSCKASG-YTFTS-----HWMHWVRQAPGQGLEWIGEFNPS---NGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYA------------------GRYFDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCSAS--SSVT-------YMYWYQQKPGKAPKLLIYD--------TSNLASGVPSRFSGSGSG--TDYTFTISSLQPEDIATYYCQQWSS-----------------------HIFTFGQGTKVEIK-
>Omalizumab:  
0 0   EVQLVES-GGGLVQPGGSLRLSCAVSG-YSITS----GYSWNWIRQAPGKGLEWVASITY----DGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFG------------------HWHFAVWGQGTLVTVSSDIQLTQSPSSLSASVGDRVTITCRAS--QSVDYD--GDSYMNWYQQKPGKAPKLLIYA--------ASYLESGVPSRFSGSGSG--TDFTLTISSLQPEDFATYYCQQSHE-----------------------DPYTFGQGTKVEIK-
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM393855.pdf
>Oportuzumab:  
EVQLVQS-GPGLVQPGGSVRISCAASG-YTFTN-----YGMNWVKQAPGKGLEWMGWINTY---TGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAI-----------------------KGDYWGQGTLLTVSSDIQMTQSPSSLSASVGDRVTITCRST--KSLLHSN-GITYLYWYQQKPGKAPKLLIYQ--------MSNLASGVPSRFSSSGSG--TDFTLTISSLQPEDFATYYCAQNLE-----------------------IPRTFGQGTKVELK-
>Pembrolizumab: 
1.7 1.7 QVQLVQS-GVEVKKPGASVKVSCKASG-YTFTN-----YYMYWVRQAPGQGLEWMGGINPS---NGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRF-------------------DMGFDYWGQGTTVTVSSEIVLTQSPATLSLSPGERATLSCRAS--KGVSTS--GYSYLHWYQQKPGQAPRLLIYL--------ASYLESGVPARFSGSGSG--TDFTLTISSLEPEDFAVYYCQHSRD-----------------------LPLTFGGGTKVEIK-
https://ec.europa.eu/health/documents/community-register/2016/20160818135470/anx_135470_it.pdf
>Pertuzumab: 
2.8 2.8 EVQLVES-GGGLVQPGGSLRLSCAASG-FTFTD-----YTMDWVRQAPGKGLEWVADVNPN---SGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPS--------------------FYFDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCKAS--QDVS------IGVAWYQQKPGKAPKLLIYS--------ASYRYTGVPSRFSGSGSG--TDFTLTISSLQPEDFATYYCQQYYI-----------------------YPYTFGQGTKVEIK-
https://ec.europa.eu/health/documents/community-register/2014/20140630129157/anx_129157_it.pdf
>Pexelizumab: h5g1.1VHC + F 
QVQLVQS-GAEVKKPGASVKVSCKASG-YIFSN-----YWIQWVRQAPGQGLEWMGEILPG---SGSTEYAQKFQGRVTMTADTSTSTAYMELSSLRSEDTAVYYCARYFFGSS------------------PNWYFVWGQGT------DIQMTQS-PSLSASVGDRVTITCGAS--ENIY------GALNWYQRKPGKAPKLLIYG--------ATNLADGVPSRFSGSGSG--TDYTLTISSLQPEDFATYYCQNVLN-----------------------TPLTFGQGTKVEIK-
>Ranibizumab: 
1 6 EVQLVES-GGGLVQPGGSLRLSCAASG-YDFTH-----YGMNWVRQAPGKGLEWVGWINTY---TGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGT----------------SHWYFDVWGQGTLVTVSSDIQLTQSPSSLSASVGDRVTITCSAS--QDIS------NYLNWYQQKPGKAPKVLIYF--------TSSLHSGVPSRFSGSGSG--TDFTLTISSLQPEDFATYYCQQYST-----------------------VPWTFGQGTKVEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf
>Trastuzumab:  
8.1 8.1   EVQLVES-GGGLVQPGGSLRLSCAASG-FNIKD-----TYIHWVRQAPGKGLEWVARIYPT---NGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDG-------------------FYAMDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCRAS--QDVN------TAVAWYQQKPGKAPKLLIYS--------ASFLYSGVPSRFSGSRSG--TDFTLTISSLQPEDFATYYCQQHYT-----------------------TPPTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf
>Vedolizumab:  
4 15 QVQLVQS-GAEVKKPGASVKVSCKGSG-YTFTS-----YWMHWVRQAPGQRLEWIGEIDPS---ESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGW------------------DYAIDYWGQGTLVTVSSDVVMTQSPLSLPVTPGEPASISCRSS--QSLAKSY-GNTYLSWYLQKPGQSPQLLIYG--------ISNRFSGVPDRFSGSGSG--TDFTLKISRVEAEDVGVYYCLQGTH-----------------------QPYTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf

HUMAN Ab:
>Adalimumab:  
2.6 26  EVQLVES-GGGLVQPGRSLRLSCAASG-FTFDD-----YAMHWVRQAPGKGLEWVSAITWN---SGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLST------------------ASSLDYWGQGTLVTVSSDIQMTQSPSSLSASVGDRVTITCRAS--QGIR------NYLAWYQQKPGKAPKLLIYA--------ASTLQSGVPSRFSGSGSG--TDFTLTISSLQPEDVATYYCQRYNR-----------------------APYTFGQGTKVEIK-
https://ec.europa.eu/health/documents/community-register/2017/20170324137210/anx_137210_it.pdf
>Denosumab OPGL-1 
1 1  EVQLLES-GGGLVQPGGSLRLSCAASG-FTFSS-----YAMSWVRQAPGKGLEWVSGITGS---GGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTV-----------------IMSWFDPWGQGTLVTVSSEIVLTQSPGTLSLSPGERATLSCRAS--QSVRG-----RYLAWYQQKPGQAPRLLIYG--------ASSRATGIPDRFSGSGSG--TDFTLTISRLEPEDFAVFYCQQYGS-----------------------SPRTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf
>Durvalumab  
3.3 3.3 EVQLVES-GGGLVQPGGSLRLSCAASG-FTFSR-----YWMSWVRQAPGKGLEWVANIKQD---GSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFG------------------ELAFDYWGQGTLVTVSSEIVLTQSPGTLSLSPGERATLSCRAS--QRVSS-----SYLAWYQQKPGQAPRLLIYD--------ASSRATGIPDRFSGSGSG--TDFTLTISRLEPEDFAVYYCQQYGS-----------------------LPWTFGQGTKVEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000ClinPharmR.pdf
>Ipilimumab:  
2 2 QVQLVES-GGGVVQPGRSLRLSCAASG-FTFSS-----YTMHWVRQAPGKGLEWVTFISYD---GNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWL---------------------GPFDYWGQGTLVTVSSEIVLTQSPGTLSLSPGERATLSCRAS--QSVGS-----SYLAWYQQKPGQAPRLLIYG--------AFSRATGIPDRFSGSGSG--TDFTLTISRLEPEDFAVYYCQQYGS-----------------------SPWTFGQGTKVEIK-
http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf
>Necitumumab:  
4.1 4.1 QVQLQES-GPGLVKPSQTLSLTCTVSG-GSISSG---DYYWSWIRQPPGKGLEWIGYIYY----SGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFG-------------------VGTFDYWGQGTLVTVSSEIVMTQSPATLSLSPGERATLSCRAS--QSVS------SYLAWYQQKPGQAPRLLIYD--------ASNRATGIPARFSGSGSG--TDFTLTISSLEPEDFAVYYCHQYGS-----------------------TPLTFGGGTKAEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
>Nivolumab: 
7.7 7.7 QVQLVES-GGGVVQPGRSLRLDCKASG-ITFSN-----SGMHWVRQAPGKGLEWVAVIWYD---GSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATND--------------------------DYWGQGTLVTVSSEIVLTQSPATLSLSPGERATLSCRAS--QSVS------SYLAWYQQKPGQAPRLLIYD--------ASNRATGIPARFSGSGSG--TDFTLTISSLEPEDFAVYYCQQSSN-----------------------WPRTFGQGTKVEIK-
https://ec.europa.eu/health/documents/community-register/2015/20150619132099/anx_132099_it.pdf
>Ofatumumab: 
0 0  EVQLVES-GGGLVQPGRSLRLSCAASG-FTFND-----YAMHWVRQAPGKGLEWVSTISWN---SGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGN-----------------YYYGMDVWGQGTTVTVSSEIVLTQSPATLSLSPGERATLSCRAS--QSVS------SYLAWYQQKPGQAPRLLIYD--------ASNRATGIPARFSGSGSG--TDFTLTISSLEPEDFAVYYCQQRSN-----------------------WPITFGQGTRLEIK-
https://ec.europa.eu/health/documents/community-register/2010/2010041974869/anx_74869_it.pdf  
>Olaratumab: 
3.5 3.5 QLQLQES-GPGLVKPSETLSLTCTVSG-GSINSS---SYYWGWLRQSPGKGLEWIGSFFY----TGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGS-------------GNYYGWFDRWDQGTLVTVSSEIVLTQSPATLSLSPGERATLSCRAS--QSVS------SYLAWYQQKPGQAPRLLIYD--------ASNRATGIPARFSGSGSG--TDFTLTISSLEPEDFAVYYCQQRSN-----------------------WPPAFGQGTKVEIK-
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761038lbl.pdf
>Ramucirumab: 9098_H 
2.2 2.2 EVQLVQS-GGGLVKPGGSLRLSCAASG-FTFSS-----YSMNWVRQAPGKGLEWVSSISSS---SSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTD-----------------------AFDIWGQGTMVTVSSDIQMTQSPSSVSASIGDRVTITCRAS--QGID------NWLGWYQQKPGKAPKLLIYD--------ASNLDTGVPSRFSGSGSG--TYFTLTISSLQAEDFAVYFCQQAKA-----------------------FPPTFGGGTKVDIK-
https://ec.europa.eu/health/documents/community-register/2014/20141219130327/anx_130327_it.pdf
>Secukinumab  
1 1 EVQLVES-GGGLVQPGGSLRLSCAASG-FTFSN-----YWMNWVRQAPGKGLEWVAAINQD---GSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDY------------YIHYWYFDLWGRGTLVTVSSEIVLTQSPGTLSLSPGERATLSCRAS--QSVSS-----SYLAWYQQKPGQAPRLLIYG--------ASSRATGIPDRFSGSGSG--TDFTLTISRLEPEDFAVYYCQQYGS-----------------------SPCTFGQGTRLEIK-
https://ec.europa.eu/health/documents/community-register/2017/20170322137073/anx_137073_it.pdf
>Zalutumumab  
QVQLVES-GGGVVQPGRSLRLSCAASG-FTFST-----YGMHWVRQAPGKGLEWVAVIWDD---GSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRG--------------VMKDYFDYWGQGTLVTVSSAIQLTQSPSSLSASVGDRVTITCRAS--QDIS------SALVWYQQKPGKAPKLLIYD--------ASSLESGVPSRFSGSESG--TDFTLTISSLQPEDFATYYCQQFNS-----------------------YPLTFGGGTKVEIK-
